Oregon Health & Science UniversityPortland, Oregon, United States
Disclosure information not submitted.
ORF28-05 - Effect of CAM2029 on Long-Term Biochemical and Symptom Control in Patients with Acromegaly and IGF-I ≤2×ULN According to Prior Injectable Somatostatin Receptor Ligand Dose: Results from ACROINNOVA 2
Sunday, June 14, 20262:15 PM - 2:30 PM CT
ORF28-06 - Efficacy and Safety of Once-Daily Oral Paltusotine in Patients with Acromegaly: Up to 2 Years in the PATHFNDR-1 and PATHFNDR-2 Open-Label Extension Studies
Sunday, June 14, 20262:30 PM - 2:45 PM CT
ORF35-03 - Osilodrostat Improves Health-Related Quality of Life in Cushing's Disease: Analysis of Patient-Reported Outcomes from the Phase III LINC 3 and LINC 4 Studies
Sunday, June 14, 20263:40 PM - 3:45 PM CT
.jpg)
.jpg)